Core Viewpoint - The company, Sichuan Kelun Pharmaceutical Co., Ltd., has disclosed its third-quarter report for 2025, ensuring the accuracy and completeness of the information provided [7][8]. Financial Data - The third-quarter financial report has not been audited [6]. - The company confirms that there are no adjustments or restatements required for previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Board Meeting Resolutions - The eighth board of directors held its ninth meeting on October 29, 2025, where all nine directors were present, and the meeting complied with legal and regulatory requirements [7][8]. - The board unanimously approved the third-quarter report with a vote of 9 in favor, 0 against, and 0 abstentions [8]. - Several internal management systems were revised and approved, including the internal audit system, information disclosure management system, and ESG management system, all receiving unanimous approval [10][12][14]. Important Matters - The company has made revisions to multiple internal management systems, including the anti-fraud system, external guarantee management system, and major event reporting system, with all revisions approved unanimously [19][20][21]. - The company has also updated its investor relations management system and securities investment management system, ensuring compliance with relevant laws and regulations [27][28]. Disclosure and Compliance - The company emphasizes the importance of accurate and complete information disclosure, with all board members bearing legal responsibility for the report's content [2][7]. - The revised internal systems and procedures will be published on the designated information disclosure website [11][31].